title: Role of tyrosine kinase inhibitors in the management of high-grade gliomas.
abstract: Recent years have witnessed an explosion of promising therapies for cancer patients. New insights into the biology of malignancies have led to the development of targeted agents with the potential to improve survival and quality of life. One of the most important classes of these compounds are tyrosine kinase inhibitors. These agents are beginning to offer a clinically relevant benefit to patients with tumors that until recently have been refractory to medical therapies. High-grade gliomas represent one class of medically refractory solid tumors. This article summarizes the state of the art of tyrosine kinase inhibitors in the management of patients with high-grade gliomas.
authors: The Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA.
authors: Manmeet S
authors: MS
authors: Ahluwalia
authors: Mital
authors: M
authors: Patel
authors: David M
authors: DM
authors: Peereboom
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D002986:Clinical Trials as Topic; D005910:Glioma / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D006801:Humans; D060787:Neoplasm Grading; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases